HTDS - Hard to Treat Diseases Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Hard to Treat Diseases Inc.

Room EF, 12F
Jinrun Mansion Shennan Boulevard
Shenzhen 518040
86 755 8272 0498

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Shimin YuanChief Exec. OfficerN/AN/AN/A
Dr. Ivana GadjanskiCommunication DirectorN/AN/AN/A
Dr. Sanja Pekovic Ph.D.Chief Strategy Officer and Chief Project ScientistN/AN/AN/A
Carol Rochibaud RobertsSec.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.

Corporate Governance

Hard to Treat Diseases Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.